Why the study?
Does acetylcholine inhibit hypoxia-induced TNF-alpha production and protect cardiomyocytes?
Does acetylcholine inhibit hypoxia-induced TNF-alpha production and protect cardiomyocytes?
Acetylcholine mediates cardioprotection against hypoxic injury in cardiomyocytes by activating the M2 receptor, regulating MAPKs phosphorylation, and down-regulating TNF-alpha production.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for M2-mediated cardioprotection in hypoxic cardiomyocytes; human translation requires prospective validation.
Recent findings have reported that up-regulation of tumor necrosis factor-alpha (TNF-α) induced by myocardial hypoxia aggravates cardiomyocyte injury. Acetylcholine (ACh), the principle vagal neurotransmitter, protects cardiomyocytes against hypoxia by inhibiting apoptosis. However, it is still unclear whether ACh regulates TNF-α production in cardiomyocytes after hypoxia. The concentration of extracellular TNF-α was increased in a time-dependent manner during hypoxia. Furthermore, ACh treatment also inhibited hypoxia-induced TNF-α mRNA and protein expression, caspase-3 activation, cell death and the production of reactive oxygen species (ROS) in cardiomyocytes. ACh treatment prevented the hypoxia-induced increase in p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) phosphorylation, and increased extracellular signal-regulated kinase (ERK) phosphorylation. Co-treatment with atropine, a non-selective muscarinic acetylcholine receptor antagonist, or methoctramine, a selective type-2 muscarinic acetylcholine (M(2) ) receptor antagonist, abrogated the effects of ACh treatment in hypoxic cardiomyocytes. Co-treatment with hexamethonium, a non-selective nicotinic receptor antagonist, and methyllycaconitine, a selective alpha7-nicotinic acetylcholine receptor antagonist, had no effect on ACh-treated hypoxic cardiomyocytes. In conclusion, these results demonstrate that ACh activates the M(2) receptor, leading to regulation of MAPKs phosphorylation and, subsequently, down-regulation of TNF-α production. We have identified a novel pathway by which ACh mediates cardioprotection against hypoxic injury in cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: